Literature DB >> 1747000

High frequency of human immunodeficiency virus-associated autonomic neuropathy and more severe involvement in advanced stages of human immunodeficiency virus disease.

S Rüttimann1, P Hilti, G A Spinas, U C Dubach.   

Abstract

We conducted a controlled trial to determine frequency and severity of autonomic neuropathy in patients infected with the human immunodeficiency virus (HIV). We studied 25 HIV-seropositive patients and 10 seronegative controls in HIV risk groups by means of five cardiovascular tests, and autonomic neuropathy was graded with a scoring system. The overall autonomic test score differed between patients and controls and was higher in patients with advanced (Centers for Disease Control class IV) disease than in those with earlier (class II or III) HIV disease. Of the patients, 60% had findings of autonomic dysfunction. Our data demonstrate a high prevalence of autonomic neuropathy in HIV-infected patients. Advanced HIV disease is associated with more severe involvement than earlier disease states.

Entities:  

Mesh:

Year:  1991        PMID: 1747000     DOI: 10.1001/archinte.1991.00400120079013

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  15 in total

1.  Patterns of immune, neuroendocrine, and cardiovascular stress responses in asymptomatic HIV seropositive and seronegative men.

Authors:  K R Starr; M H Antoni; B E Hurwitz; M S Rodriquez; G Ironson; M A Fletcher; M Kumar; R Patarca; S K Lutgendorf; R E Quillian; N G Klimas; N Schneiderman
Journal:  Int J Behav Med       Date:  1996

2.  The symptoms of autonomic dysfunction in HIV-positive Africans.

Authors:  Caterina Compostella; Leonida Compostella; Ruggiero D'Elia
Journal:  Clin Auton Res       Date:  2007-12-15       Impact factor: 4.435

3.  Post-exercise heart rate recovery in HIV-positive individuals on highly active antiretroviral therapy. Early indicator of cardiovascular disease?

Authors:  W T Cade; D N Reeds; S Lassa-Claxton; V G Davila-Roman; A D Waggoner; W G Powderly; K E Yarasheski
Journal:  HIV Med       Date:  2007-12-18       Impact factor: 3.180

4.  Heart rate variability and autonomic function tests in HIV positive individuals in India.

Authors:  Ankit Sakhuja; Ankur Goyal; Ashok Kumar Jaryal; Naveet Wig; Madhu Vajpayee; Ajay Kumar; Kishore Kumar Deepak
Journal:  Clin Auton Res       Date:  2007-03-27       Impact factor: 4.435

5.  Autonomic and cardiovascular function in HIV spectrum disease: early indications of cardiac pathophysiology.

Authors:  K A Brownley; J R Milanovich; S J Motivala; N Schneiderman; L Fillion; J A Graves; N G Klimas; M A Fletcher; B E Hurwitz
Journal:  Clin Auton Res       Date:  2001-10       Impact factor: 4.435

Review 6.  A meta-analysis of HIV and heart rate variability in the era of antiretroviral therapy.

Authors:  Roger C McIntosh
Journal:  Clin Auton Res       Date:  2016-07-09       Impact factor: 4.435

7.  Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea.

Authors:  D Sharpstone; P Neild; R Crane; C Taylor; C Hodgson; R Sherwood; B Gazzard; I Bjarnason
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

8.  Delayed gastric emptying in human immunodeficiency virus infection: correlation with symptoms, autonomic function, and intestinal motility.

Authors:  P J Neild; K S Nijran; E Yazaki; D F Evans; D L Wingate; R Jewkes; B G Gazzard
Journal:  Dig Dis Sci       Date:  2000-08       Impact factor: 3.199

9.  Heart rate variability and heart rate turbulence in HIV-infected patients receiving combination antiretroviral therapy.

Authors:  Wanwarang Wongcharoen; Kolakrit Khienprasit; Arintaya Phrommintikul; Apichard Sukonthasarn; Nipon Chattipakorn
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-06-09       Impact factor: 1.468

10.  Autonomic dysfunction is common in HIV and associated with distal symmetric polyneuropathy.

Authors:  Jessica Robinson-Papp; Sandeep Sharma; David M Simpson; Susan Morgello
Journal:  J Neurovirol       Date:  2013-04-12       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.